Extension to the temporary Medical Transportation mileage rate - First Nations Health Authority
This story deserves to be shared
Send it to someone who'd care, or post it on your networks.
This article is an excerpt. To read the full content, visit the original source. First Nations Health Authority
Related articles

Updates to Medical Transportation Benefit client forms - First Nations Health Authority
HomeNewsUpdates to Medical Transportation Benefit client forms October 8, 2026FNHA infoBenefits The First Nations Health Authority (FNHA) is committed to providing accessible, efficient, and Client-centered services. As part of this commitment, Medical Transportation (MT) Client forms have been updated to reflect current program operations, make them easier to complete and help streamline the processing of travel requests and reimbursements.
Government Announces Major Enhancements to Medical Transportation Assistance and Improved Access to Health Care - Government of Newfoundland and Labrador
Medical transportation benefit updates: Extension to the temporary mileage rate - First Nations Health Authority

Continuous glucose monitors help type 2 diabetes patients spend 5 more hours a day in healthy blood sugar range - Medical Xpress
Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.
Wearing headphones during surgery may reduce nausea and vomiting afterward - Medical Xpress
Patients who wore noise-canceling headphones during minimally invasive gynecological surgery were significantly less likely to experience postoperative nausea and vomiting (PONV), suggest findings from a randomized clinical trial presented at the Anesthesiology 2026 annual meeting.

Kefah Mokbel: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? - Oncodaily
“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.
0 comments
No comments yet. Be the first to share your thoughts!